NCT04245865 2026-04-03
Toco-CoR
Vejle Hospital
Phase 2 Active not recruiting
Clinical Trials
149 trialsNCT07281768 2026-03-20
Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Not yet recruiting
NCT05489211 2026-03-19
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
AstraZeneca
Phase 2 Recruiting
NCT04430738 2026-02-24
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
Seagen Inc.
Phase 2 Active not recruiting
NCT07407465 2026-02-17
CHIMERA
Gruppo Oncologico del Nord-Ovest
Phase 2 Recruiting
NCT07395063 2026-02-09
A Clinical Study on the Treatment of Metastatic Colorectal Cancer at the Second-line or Beyond.
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Phase 2 Not yet recruiting
NCT07229846 2026-01-08
A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation
Harbin Medical University
Phase 2 Not yet recruiting
NCT02955940 2025-12-17
An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib
Incyte Corporation
Phase 2 Active not recruiting
NCT07243938 2025-11-24
Phase II Basket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET)
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Not yet recruiting
NCT03984578 2025-11-18
Window of Opportunity Study in Colorectal Cancer
National Cancer Centre, Singapore
Phase 2 Completed
NCT07233850 2025-11-18
A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers
Shenyang Sunshine Pharmaceutical Co., LTD.
Phase 2 Not yet recruiting
NCT05382442 2025-10-14
A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer
Akeso
Phase 2 Active not recruiting
NCT07215936 2025-10-14
Dose-dense Capecitabine Schedule [7days on _7 Days Off] in Colorectal Cancer in Comparison With Standered Regimen
Sohag University
Phase 2 Active not recruiting
NCT03929666 2025-09-12
A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
Jazz Pharmaceuticals
Phase 2 Completed
NCT02978612 2025-09-05
ACE
Oslo University Hospital
Phase 2 Completed
NCT07134101 2025-08-29
SMARTi-RC01
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Not yet recruiting
NCT06991465 2025-05-28
Hypo-OPRA
McGill University Health Centre/Research Institute of the McGill University Health Centre
Phase 2 Recruiting
NCT06888843 2025-03-27
AHTCRR-1
Nizhny Novgorod Regional Clinical Oncology Center
Phase 2 Recruiting
NCT03396926 2025-02-28
Pembrolizumab, Capecitabine, and Bevacizumab for Treating Colorectal Cancer
University of California, San Francisco
Phase 2 Completed
NCT00961571 2025-02-12
Sunitinib and Capecitabine for First Line Colon Cancer
Georgetown University
Phase 2 Terminated
NCT03117972 2025-02-05
CLavSyn
Centre Hospitalier Universitaire de Besancon
Phase 2 Terminated
NCT02780700 2025-02-03
Nintedanib Alone or in Combination With Capecitabine in Refractory Metastatic Colorectal Cancer [LUME-Colon 2]
Boehringer Ingelheim
Phase 2 Terminated
NCT01531595 2024-12-12
AXOAXI
Helsinki University Central Hospital
Phase 2 Active not recruiting
NCT06405139 2024-11-29
Nanoliposomal Irinotecan, Oxaliplatin Plus Capecitabine As Conversion Therapy of Locally Advanced Colorectal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT06493760 2024-09-19
A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Phase 2 Recruiting
NCT02873195 2024-08-23
Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer
Academic and Community Cancer Research United
Phase 2 Completed
NCT02743221 2024-08-20
TASCO1
Servier
Phase 2 Completed
NCT02842580 2024-07-10
HIGH-LIGHT
Federation Francophone de Cancerologie Digestive
Phase 2 Terminated
NCT06148402 2024-05-13
Fruquintinib Plus Camrelizumab and Capecitabine as Salvage Therapy After Progression on FOLFOXIRI-based First-line Treatment in Patients With Unresectable/Metastatic Colorectal Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Recruiting
NCT02291289 2024-05-06
MODUL
Hoffmann-La Roche
Phase 2 Completed
NCT06234007 2024-03-18
Short-course Radiotherapy Followed by Fruquintinib Plus Adebrelimab and CAPOX in the Full Course Neoadjuvant Treatment of Locally Advanced Rectal Cancer: a Multicenter, Single-arm, Open-label Study
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Recruiting
NCT06192680 2024-01-18
Liposomal Irinotecan and Capecitabine Plus Bevacizumab as Second-line Therapy in Metastatic Colorectal Cancer
Harbin Medical University
Phase 2 Not yet recruiting
NCT05578287 2023-12-07
DETECT
Sun Yat-sen University
Phase 2 Unknown
NCT01776307 2023-11-15
A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
Sumitomo Pharma America, Inc.
Phase 2 Completed
NCT04310176 2023-11-13
REVOLUTION
National Cancer Institute, Naples
Phase 2 Unknown
NCT04259944 2023-09-28
Post-surgical Liquid Biopsy-guided Treatment of Stage III and High-risk Stage II Colon Cancer Patients: the PEGASUS Trial
IFOM ETS - The AIRC Institute of Molecular Oncology
Phase 2 Unknown
NCT05799820 2023-05-25
QL1706 Monotherapy or in Combination With Bevacizumab and XELOX as First-line Treatment of Unresectable Advanced or Metastatic CRC
Qilu Pharmaceutical Co., Ltd.
Phase 2 Unknown
NCT05794750 2023-04-06
AK104-IIT-13
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Not yet recruiting
NCT04304209 2023-02-01
Pd1 Antibody Sintilimab ± Chemoradiotherapy for Locally Advanced Rectal Cancer
Sun Yat-sen University
Phase 2 Active not recruiting
NCT05659290 2023-01-06
Alternating Treatment With Fruquintinib and Bevacizumab Plus Capecitabine as Maintenance Therapy After First-Line Treatment in Metastatic Colorectal Cancer
Nanfang Hospital, Southern Medical University
Phase 2 Unknown
NCT00954876 2022-10-20
Study of Capecitabine and Cetuximab as First-Line Therapy in Patients With Metastatic Wild Type Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Colorectal Cancer
Translational Genomics Research Institute
Phase 2 Withdrawn
NCT04733963 2022-07-26
Fruquintinib Plus Capecitabine Versus Bevacizumab Plus Capecitabine as Maintenance Therapy Following First-line Treatment for Metastatic Colorectal Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Unknown
NCT04080843 2022-07-13
ALTER-C-002
Zhejiang University
Phase 2 Completed
NCT05451719 2022-07-12
Fruquintinib Plus Capecitabine Versus Capecitabine as Maintenance Therapy for Metastatic Colorectal Cancer After First-line Chemotherapy
Fudan University
Phase 2 Unknown
NCT01759238 2022-07-01
OLGA
Universitätsklinikum Hamburg-Eppendorf
Phase 2 Terminated
NCT04247984 2022-03-11
A Comparison of mXELIRI Regimen and FOLFIRI Combined Bevacizumab Regimen as First-line Chemotherapy Regimen for Metastatic Colorectal Cancer
ChineseAMS
Phase 2 Completed
NCT04911517 2022-02-23
Neoadjuvant Chemoradiotherapy Plus Tislelizumab Followed by TME for LARC.
Beijing Friendship Hospital
Phase 2 Unknown
NCT05200299 2022-01-20
mFOLFOXIRI Compared to mFOLFOX6 or CapeOx as Adjuvant Chemotherapy for Stage IIIB or IIIC Colorectal Cancer
First Affiliated Hospital of Wenzhou Medical University
Phase 2 Unknown
NCT00321100 2022-01-12
Combination of Cetuximab, Capecitabine, and Oxaliplatin With or Without Bevacizumab
Fox Chase Cancer Center
Phase 2 Terminated
NCT03050814 2021-12-20
Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated